-
Product Insights
NewBile Acid Receptor – Drugs In Development, 2024
The Bile Acid Receptor pipeline drugs market research report outlays comprehensive information on the Bile Acid Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Gastrointestinal, Metabolic Disorders, Undisclosed, and Genetic Disorders which include indications of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Type 2 Diabetes, Hyperlipidemia, Unspecified, and Alport Syndrome. It also reviews...
-
Product Insights
NewPeroxisome Proliferator Activated Receptor Alpha – Drugs In Development, 2024
The Peroxisome Proliferator Activated Receptor Alpha pipeline drugs market research report outlays comprehensive information on the Peroxisome Proliferator Activated Receptor Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Gastrointestinal, Metabolic Disorders, Ophthalmology, and Central Nervous System which include indications of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Type 2 Diabetes, Hyperlipidemia, Dry (Atrophic)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Biliary Atresia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maralixibat Chloride in Biliary Atresia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maralixibat Chloride in Biliary Atresia Drug Details: Maralixibat chloride (Livmarli)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemafibrate in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemafibrate in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemafibrate in Primary Biliary Cholangitis (Primary Biliary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Transitional Cell Carcinoma (Urothelial Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maralixibat Chloride in Primary Sclerosing Cholangitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maralixibat Chloride in Primary Sclerosing Cholangitis Drug Details: Maralixibat...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etrasimod in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etrasimod in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etrasimod in Crohn's Disease (Regional Enteritis) Drug Details: Etrasimod...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Setanaxib in Kidney Disease (Nephropathy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Setanaxib in Kidney Disease (Nephropathy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Setanaxib in Kidney Disease (Nephropathy) Drug Details: Setanaxib (GKT-831; GKT-137831)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPG-1860 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPG-1860 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPG-1860 in Primary Biliary Cholangitis (Primary Biliary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Foscenvivint in Adrenocortical Carcinoma (Adrenal Cortex Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Adrenocortical Carcinoma (Adrenal Cortex Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Foscenvivint in Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drug...